{"id":"https://genegraph.clinicalgenome.org/r/311256a2-daf8-42c6-8700-913401df1e02v1.1","type":"EvidenceStrengthAssertion","dc:description":"**Note: In September 2021, the ClinGen Epilepsy GCEP opted to change the disease term on this curation from infantile epilepsy syndrome to developmental and epileptic encephalopathy. The evidence summary below reflects this change. The original evidence and conclusion remains the same; therefore, the original date of approval has not been changed. **\n\nApproved by the ClinGen Epilepsy Expert Panel 10/20/2017.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/311256a2-daf8-42c6-8700-913401df1e02","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2017-10-20T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2021-10-04T20:43:30.655Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7caca6c-e942-40e1-9ef5-22cfbbb68bf7","type":"EvidenceLine","dc:description":"Splice site mutation. Variant Evidence: Figure 2 shows that the mutation at the splice site causes alteration in the coding sequence, and presumbaly a premature stop codon. qRT_PCR of the patients blood shows 50% reduced STXBP1 expression, suggesting LOF mutation.This is a denovo mutation that is LOF, with cofirmed maternity and paternity, so increase points to max. Upgraded to be consistent with SOP v5.","calculatedScore":5.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7caca6c-e942-40e1-9ef5-22cfbbb68bf7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18703708","allele":{"id":"https://genegraph.clinicalgenome.org/r/2da141cd-df05-4052-9baf-7f11137e2010","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001032221.6(STXBP1):c.169+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/6731"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d7caca6c-e942-40e1-9ef5-22cfbbb68bf7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Figure 2 shows that the mutation at the splice site causes alteration in the coding sequence, and presumbaly a premature stop codon. qRT_PCR of the patients blood shows 50% reduced STXBP1 expression, suggesting LOF mutation.This is a denovo mutation that is LOF, with cofirmed maternity and paternity, so increase points to max.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/d1db92d3-43e4-4181-859d-76cde773ca76","type":"EvidenceLine","dc:description":"Maternity and paternity confirmed. Variant Evidence: Circular dichroism shows destabilization of the C180Y variant, and it unfolded at a much lower temperature than WT STXBP1 (Figure 4B,C). The C180Y variant had reduced binding to STX1A (syntaxin) compared to WT (Fig. 4D-E). The C180Y variant also showed abnormal clustering when expessed in N2A cells compared to WT (Suppl Fig 1). In original curation, this score was upgraded to 3 points. Due to the limitations of the GCI, a score of 3 cannot be selected for a de novo missense variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d1db92d3-43e4-4181-859d-76cde773ca76_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18469812","allele":{"id":"https://genegraph.clinicalgenome.org/r/72237d27-412a-458e-bae3-e8b103f19b36","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001032221.6(STXBP1):c.539G>A (p.Cys180Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/6727"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d1db92d3-43e4-4181-859d-76cde773ca76_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Circular dichroism shows destabilization of the C180Y variant, and it unfolded at a much lower temperature than WT STXBP1 (Figure 4B,C). The C180Y variant had reduced binding to STX1A (syntaxin) compared to WT (Fig. 4D-E). The C180Y variant also showed abnormal clustering when expessed in N2A cells compared to WT (Suppl Fig 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/ca3d003e-29ad-4597-8a7a-b8d46a0fe028","type":"EvidenceLine","dc:description":"Note: not a true de novo as the father was not tested due to death, so you cannot rule out potential segregation and penetrance issues. Variant Evidence: N2A cells transiently transfected with G544D variant show aggregation of the variant and irregular distribution compared to WT (Suppl Figure 1). No other testing for gene mutations though, so cannot rule out the potential of mutations in other EIEE genes from deceased father, score down pending expert review.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ca3d003e-29ad-4597-8a7a-b8d46a0fe028_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18469812","allele":{"id":"https://genegraph.clinicalgenome.org/r/262b2916-eaf6-4a3d-ab62-ec5acefdb94e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001032221.6(STXBP1):c.1631G>A (p.Gly544Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/6726"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e1cc2b54-25da-4bba-a5ae-2cfe60d70f88","type":"EvidenceLine","dc:description":"Maternity and paternity confirmed. Variant Evidence: the V84D variant showed abnormal clustering in N2A cells compared to WT STXBP1 (Suppl Fig 1). In original curation, this score was upgraded to 2.5 points. Due to the limitations of the GCI, a score of 2.5 cannot be selected for a de novo missense variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1cc2b54-25da-4bba-a5ae-2cfe60d70f88_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18469812","allele":{"id":"https://genegraph.clinicalgenome.org/r/d315e0b3-0940-4da9-9a90-98ae9ee70556","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001032221.6(STXBP1):c.251T>A (p.Val84Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/6729"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e1cc2b54-25da-4bba-a5ae-2cfe60d70f88_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"the V84D variant showed abnormal clustering in N2A cells compared to WT STXBP1 (Suppl Fig 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/dda4d2b3-ee96-4565-859d-70cc081bf15f","type":"EvidenceLine","dc:description":"This is a LOF mutation, but de novo with confirmed maternity and paternity, so increase points to max. This is a LOF mutation, but de novo with confirmed maternity and paternity, so increase points to max.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dda4d2b3-ee96-4565-859d-70cc081bf15f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18703708","allele":{"id":"https://genegraph.clinicalgenome.org/r/a421d3b7-04b4-4b48-a806-a17562661ad7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001032221.6(STXBP1):c.1162C>T (p.Arg388Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/6730"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/34fe895e-db50-4e41-8b3b-23f29974560d","type":"EvidenceLine","dc:description":"Maternity and paternity confirmed. Variant Evidence: the M443R variant showed abnormal clustering in N2A cells compared to WT STXBP1 (Suppl Fig 1). In original curation, this score was upgraded to 2.5 points. Due to the limitations of the GCI, a score of 2.5 cannot be selected for a de novo missense variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34fe895e-db50-4e41-8b3b-23f29974560d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18469812","allele":{"id":"https://genegraph.clinicalgenome.org/r/3fca0ccb-db0a-460e-a42a-809f7109029f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001032221.6(STXBP1):c.1328T>G (p.Met443Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/6728"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/34fe895e-db50-4e41-8b3b-23f29974560d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"the M443R variant showed abnormal clustering in N2A cells compared to WT STXBP1 (Suppl Fig 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":10.75},{"id":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e381fbc-59fb-424a-8f92-f3d722762927","type":"EvidenceLine","dc:description":"Functional Expression","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20ed3846-6fd8-4618-9456-51c35e884c14","type":"Finding","dc:description":"cloned and characterized the expression of ratSTXBP1 (n-Sec1) in developeing rat tissue. Northrn Blot dot blot analysis showed high STXBP1 expression in the brain and spinal cord, 100x more than in other tissues. STXBP1 was shown to express in other tissues (including heart, spleen, lung, liver, muscle, kidney, and testis) but only after long overexposure of the autoradiogram. They also showed temporal expression of STXBP1 in the developing rat brain. Low levels of STXBP1 are seen at E16 and increase to a maximum level at P7, concomitant with synapse formation. Also performed western blot to show restricted expression of SSTXBP1 in the brain (regions include cerebellum, thalamus, hippocampus, corpus callosum, cerebral cortex, olfactory bulb).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8108429","rdfs:label":"rSTXBP1 developmental expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0fe7ef4e-b1aa-4632-8168-c63d1d6c5db6","type":"EvidenceLine","dc:description":"Also mapped STXBP1 to chormosome 9q34.1 by FISH.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b6fec6e3-a30a-4050-9068-a3bcff93379d","type":"Finding","dc:description":"Northern blot analysis of human tissue shows expression of STXBP1 preferentially in the brain, with low levels in other  tissues for the \"short\" isoform (Fig. 1). ID's alternatively spliced \"longer\" isoform of STXBP1 that has restricted expression in the brain (cerebellum) and retina (Fig. 2).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9545644","rdfs:label":"STXBP1 human expression","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/af98a203-d5a2-48be-99f5-1664ad6ad821","type":"EvidenceLine","dc:description":"Note: placed in biochemical as this interaction is required for STXBP1 function, but ATX1A is not a EIEE gene, therefore we cannot count as protein interactions per the SOP. Plus several other papers show this association as being important including the Saitsu et al., 2008, so can give increased points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a63e584-f533-460e-a999-a93ba7fc6cdd","type":"Finding","dc:description":"Show that STXBP1 and STX1A (syntaxin) bind at a 1:1 ratio (glycerol gradients, Fig 4)). They confirmed the binding with in vitro binding assays (Fig 5) , and found that STXBP1 also bound STX2, STX3 but not STX4.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8108429","rdfs:label":"STXBP1 binding to STX1A","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1cb01b72-1ad1-4f4c-99e9-612478e090f1","type":"EvidenceLine","dc:description":"increased points due to amount of data shown and tested.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/366f4dcf-8d92-4075-8f6f-c5151842f169","type":"FunctionalAlteration","dc:description":"Shows STXBP1 expression is required for neuronal survival. No changes to neuron shape, dendritic aborization, or synapse numbers in STXBP1 het vs. WT cells. Dendritic length and branching were unchanged (opposite effect then what was seen in Yamashita 2016 in patient cells). No changes to the number or size of synapses per dendritic segment were observed.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26280581","rdfs:label":"FA Np Cells"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/19a93458-1d75-4fc8-9f87-c2d6c1300b2a","type":"EvidenceLine","dc:description":"The reduction in STX1A levels and mislocalization is to be expected, and the change in neurite extension is new, but it would have been nice to show changes in synpatic transmission in these cells, scored down to 0.5","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bbd7f44f-6193-4367-903f-1470efe0638e","type":"FunctionalAlteration","dc:description":"Generated human STXBP1-R367X iPSC-derived neurons. Karyotyping of iPSCs from patient and control were normal. Both control and R367X iPSCs differentiated into neruons similarly, and expressed the appropriate markers. qRT-PCR and western blot showed 50% reductino of STXBP1 levels in the R367X iPSC-derived neurons compared to the controls (Fig 1D). Interestingly, qRT-PCr analysis showed increased expression of GRIN2A, GRIN2Bm and NKCC1 in the R367X cells compared to controls.WEstern blot showed reduced expression of STX1A in the R367X cells, but IHC showed that the localization of STX1A had changed, and was forming aggregates in the cytoplasm and not at the cell membrane as in controls. STXBP1-R367X cells also showed reduced neurite extension compared to controls. Note: iPSCs derived from the patients father were used as controls. Patient was male (Japanese), presented with focal motor seizures in neonatla perios and eplileptic spasms arain MRI showed hypoplasia of corpus callosum and EEG showed suppression burst pattern. STXBP1 c.1009C>T, p. R367X variant. RTx phenobarbital, ACTH, zonisamide, valporate, and clobazam (ineffective). RTx levetiracetam, seizures stopped, has profound psychomotor retardation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26918652","rdfs:label":"human iPSCs EIEE model"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a8d21800-652f-431b-a5d8-4208d4e91d46_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e78ef7a-a76f-403b-9a9c-f80ca93f2d58","type":"EvidenceLine","dc:description":"Conclusion: STXBP1 mutation causes ~2 fold decrease in synpatic strength in excitatory neurons.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/250e9176-1f6f-4bc6-9e84-ec1b9a418847","type":"Finding","dc:description":"Co-expressing STXBP1 that is controlled by light allows for rescue of STXBP1 expression.  The STXBP1 neurons exhibited ~2-fold decrease in EPSC amplitude. RE-expression of WT-STXBP1 in the het cells 5 days before stimulation completely rescued the reduced EPSC amplitude, suggesting that STXBP1 loss in neurons results in a presynaptic impairment. No changes in coeeficient of variation and Ca2+-triggered release were observed between STBP1 het and WT iNeurons.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26280581","rdfs:label":"Rescue in Engineered Equivalent","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/90d9b277-34b3-4114-8327-b1e6e2345b12","type":"EvidenceLine","dc:description":"Unfortunately, they did not study the heterozygus mice in this paper. Twenty three other papers reference this mouse model.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24f9e24f-5619-41cd-80bb-b3b1ed7ea7b6","type":"Finding","dc:description":"Generated conventional STXBP1 knockout mice replacing 5 exons (encoding AA 14-144) with a neomycin selection cassette through homologous recombination. Homozygous null STXBP1 mice are completely paralyzed, are born at term but die immediately after birth (respiration problems). STXBP1 null mice lack neurotransmission in E18 neocortical slices. Synaptic events were absent from E15-E18 diaphraghm neuromuscular junctions in STXBP1. nu,, mice compared to WT. Interestingly, brain structure was intact, with no diffreence observed between STXBP1 null and WT mice, but massive cell death was observed in the brains of STXBP1 null mice at E14.5 and progressing to E18.5, and was attributed to apoptosis (TUNEL+ apoptotic bodies present). Northern and Western blot confirm loss of STXBP1 expression in homozygous null mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10657302","rdfs:label":"Animal Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":3463,"specifiedBy":"GeneValidityCriteria5","strengthScore":16.75,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Bhr65WJwzTQ","type":"GeneValidityProposition","disease":"obo:MONDO_0100062","gene":"hgnc:11444","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a8d21800-652f-431b-a5d8-4208d4e91d46-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}